Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
NCT ID: NCT04457687
Last Updated: 2025-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication
NCT01858870
Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)
NCT04437004
A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
NCT03198949
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
NCT01465997
European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)
NCT01991041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorcaserin
Lorcaserin 10 milligram (mg) tablets orally.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, age at least 2 years at the time of informed consent
3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
4. Has a clinical benefit from lorcaserin in the opinion of the treating physician
Exclusion Criteria
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
David Geffen School of Medicine, UCLA Mattel Children's Hospital
Los Angeles, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Pena
Avon, Connecticut, United States
(Resor)
Greenwich, Connecticut, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Clinical Neurosciences of Tampa Bay
Clearwater, Florida, United States
Miami Children's Hospital - Nicklaus Children's Hospital Miami
Miami, Florida, United States
Mid-Atlantic Epilepsy and Sleep Center - Bethesda
Bethesda, Maryland, United States
University of Missouri Health Care
Columbia, Missouri, United States
Northeastern Regional Epilepsy Group (Hackensack)
Hackensack, New Jersey, United States
New York Medical College
Hawthorne, New York, United States
NYU Langone Comprehensive Epilepsy Center
New York, New York, United States
Mt. Sinai School of Medicine
New York, New York, United States
University Hospital Cleveland Medical Center
Cleveland, Ohio, United States
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Alberta Children's Hospita
Calgary, Alberta, Canada
Stollery Children's Hospital
Edmonton, Alberta, Canada
BC Children's Hospital
Vancouver, British Columbia, Canada
Children's Hospital - VH, London Health Sciences Centre
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2023-A001-405
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.